SLC5A2 and type 2 diabetes mellitus: While many other interesting and clinically relevant questions arise about other potential genotype-specific responses to therapy in monogenic IR, the small size or absence of other genotype by treatment groups precluded the drawing of conclusions about risks and benefits, including for very widely used medications such as metformin26,47–49, newer agents commonly used in type 2 diabetes including SGLT2 inhibitors50,51 and GLP-1 agonists, and non pharmacologic interventions such as bariatric surgery52–54.